Table 2.
Correlation of TGF-βRII and pSmad2 expressions with clinicopathological parameters of breast cancer, Shanghai Breast Cancer Study, Phase II
| TGFβ-RII intensity (No. of cases/%)
|
TGFβ-RII subcellular pattern (No. of cases/%)
|
pSmad2 intensity (No. of cases/%)
|
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| 0–1 | 2 | 3 | P | 1c | 2d | P | 0–1 | 2 | 3 | P | |
| Age at diagnosis (mean±SD)a | 53.5±8.8 | 50.9±8.1 | 51.6±8.5 | 0.03 | 50.3±7.9 | 51.7±8.5 | 0.04 | 51.5±8.3 | 51.3±8.6 | 51.6± − 8.3 | 0.93 |
| Menopausal status | |||||||||||
| Pre-menopause | 39/7.5 | 224/43.2 | 256/49.3 | 97/18.7 | 422/81.3 | 97/18.7 | 144/27.7 | 278/53.6 | |||
| Post-menopause | 55/12.6 | 176/40.6 | 204/46.8 | 0.03 | 62/14.2 | 374/85.8 | 0.06 | 83/19.0 | 133/30.5 | 220/50.5 | 0.58 |
| Family history (BC) | |||||||||||
| No | 88/9.7 | 380/41.8 | 441/48.5 | 156/17.2 | 753/82.8 | 171/18.8 | 265/29.2 | 473/52.1 | |||
| Yes | 6/13.0 | 21/45.7 | 19/41.3 | 0.57 | 3/6.5 | 43/93.5 | 0.06 | 9/19.6 | 12/26.1 | 25/54.3 | 0.90 |
| BMI (mean±SD) a | 24.3±3.3 | 24.3±3.1 | 24.1±3.4 | 0.57 | 25.1±3.7 | 24.0±3.1 | <0.01 | 24.1±3.4 | 24.2±3.4 | 24.2±3.1 | 0.92 |
| Tumor size | |||||||||||
| <=2 cm | 38/9.6 | 161/40.6 | 198/49.9 | 62/15.6 | 335/84.4 | 82/20.7 | 119/30.0 | 196/49.4 | |||
| >2 cm | 50/9.9 | 214/42.3 | 242/47.8 | 0.83 | 87/17.2 | 419/82.8 | 0.53 | 88/17.4 | 138/27.3 | 280/55.3 | 0.19 |
| Histological type | |||||||||||
| Non-invasive | 2/11.8 | 4/23.5 | 11/64.7 | 7/41.2 | 10/58.8 | 5/29.4 | 6/35.3 | 6/35.3 | |||
| IDC | 71/9.7 | 303/41.5 | 356/48.8 | 119/16.3 | 611/83.7 | 133/18.2 | 205/28.1 | 392/53.7 | |||
| ILC | 4/10.3 | 24/61.5 | 11/28.2 | 3/7.7 | 36/92.3 | 4/10.3 | 13/33.3 | 22/56.4 | |||
| Other | 14/9.2 | 64/42.1 | 74/48.7 | 0.16b | 26/17.1 | 126/82.9 | 0.03b | 36/23.7 | 44/28.9 | 72/47.4 | 0.27b |
| Histological grade | |||||||||||
| I | 7/4.6 | 68/44.4 | 78/51.0 | 27/17.7 | 125/82.3 | 47/30.7 | 40/26.1 | 66/43.1 | |||
| II | 48/10.1 | 200/42.0 | 228/47.9 | 77/16.2 | 399/83.8 | 86/18.1 | 143/30.0 | 247/51.9 | |||
| III | 38/11.8 | 132/41.1 | 151/47.0 | 0.18 | 54/16.8 | 267/83.2 | 0.91 | 45/14.0 | 94/29.3 | 182/56.7 | <0.01 |
| TNM stage | |||||||||||
| 0–I | 25/8.2 | 132/43.4 | 147/48.4 | 54/17.7 | 250/82.2 | 70/23.0 | 91/29.9 | 143/47.0 | |||
| IIa | 24/7.8 | 129/41.7 | 156/50.5 | 54/17.5 | 255/82.5 | 53/17.2 | 89/28.8 | 167/54.0 | |||
| IIb | 32/15.2 | 78/37.0 | 101/47.9 | 33/15.6 | 178/84.4 | 37/17.5 | 55/26.1 | 119/56.4 | |||
| III–IV | 9/8.0 | 56/50.0 | 47/42.0 | 0.04 | 14/12.5 | 98/87.5 | 0.58 | 16/14.3 | 34/30.4 | 62/55.4 | 0.23 |
| ER | |||||||||||
| Positive | 52/8.6 | 256/42.4 | 296/49.0 | 111/18.4 | 493/81.6 | 115/19.0 | 178/29.5 | 311/51.5 | |||
| Negative | 42/12.1 | 144/41.4 | 162/46.6 | 0.22 | 47/13.5 | 301/86.5 | 0.05 | 65/18.7 | 98/28.2 | 185/53.2 | 0.88 |
| PR | |||||||||||
| Positive | 47/7.9 | 254/42.7 | 294/49.4 | 109/18.3 | 486/81.7 | 116/19.5 | 164/27.6 | 315/53.0 | |||
| Negative | 47/13.3 | 144/40.8 | 162/45.9 | 0.03 | 48/13.6 | 305/86.4 | 0.06 | 64/18.1 | 110/31.2 | 179/50.7 | 0.49 |
| HER2 | |||||||||||
| Positive | 28/10.1 | 107/38.6 | 142/51.3 | 39/14.1 | 238/85.9 | 52/18.8 | 86/31.0 | 139/50.2 | |||
| Negative | 59/9.9 | 257/43.0 | 282/47.2 | 0.47 | 105/17.6 | 493/82.4 | 0.20 | 110/18.4 | 168/28.1 | 320/53.5 | 0.61 |
| Molecular type | |||||||||||
| Luminal A | 38/9.2 | 174/42.2 | 200/48.5 | 79/19.2 | 333/80.8 | 73/17.7 | 119/28.9 | 220/53.4 | |||
| Luminal B | 11/8.2 | 53/39.3 | 71/52.6 | 23/17.0 | 112/83.0 | 30/22.2 | 43/31.9 | 62/45.9 | |||
| HER2 | 16/15.0 | 39/36.5 | 52/48.6 | 13/12.1 | 94/87.9 | 13/12.2 | 33/30.8 | 61/57.0 | |||
| TN | 14/12.1 | 46/39.7 | 56/48.3 | 0.56 | 14/12.1 | 102/87.9 | 0.16 | 25/21.6 | 30/25.9 | 61/52.6 | 0.36 |
a
Age-adjusted results are presented.
b
Monte Carlo simulation
c
Membranous predominant
d
Cytoplasmic or membranous cytoplasmic